INCY - Incyte Corporation
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic.
As of May 15, 2026: spot at $95.93, ATM IV 40.1%, max pain $105.00, net GEX -$714.2K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $19.74B
- P/E Ratio
- 13.76
- Beta
- 0.80
- 52-Week Range
- 61.11-112.29
- CEO
- William J. Meury
- Employees
- 2,617
- IPO Date
- Nov 4, 1993
- Exchange
- NASDAQ
What INCY Looks Like to Options Traders Today
IV rank of 45.6% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; negative net gamma exposure (-$714.2K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (-0.023) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The INCY overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked INCY overview questions
- What is INCY?
- INCY is the ticker symbol for Incyte Corporation, a listed security. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Listed on NASDAQ. INCY is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the INCY options snapshot look like today?
- As of May 15, 2026, the INCY options snapshot shows spot at $95.93, ATM IV 40.1%, IV rank 45.6%, max pain $105.00, net GEX -$714.2K, expected move 11.50%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are INCY's key statistics?
- Incyte Corporation (INCY) carries a market capitalization of $19.74B, trailing P/E ratio of 13.76, beta of 0.80 relative to the broader market, 52-week range of 61.11-112.29. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does INCY belong to?
- Incyte Corporation operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare INCY's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the INCY data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).